Lenalidomide plus rituximab achieves 87% response rate
First-line combination biologic therapy with lenalidomide plus rituximab produced an 87% overall response rate in stage 3-4 mantle cell lymphoma, in an industry-sponsored, phase II clinical trial reported online Nov. 5 in the New England Journal of Medicine.
Mantle cell lymphoma is generally...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Clinical Trials | Dermatology | Lymphoma | Revlimid | Rituxan | Skin